Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Mesenchymal Stem Cell Conditioned Medium for Spinal Canal Stenosis
jRCT1051240277Recruiting
- Sponsor
- Seihoku Clinic
- Start
- Feb 2025
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in spinal stenosis, sponsored by Seihoku Clinic. Primary endpoints: Subjective symptoms and Blood C-reactive protein (CRP). Started Feb 2025; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
spinal stenosis
Beyond the preview
Go deeper on jRCT1051240277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051240277.